Oral semaglutide (revision 1)
Old revision·00:36, 1 Sep 2024·IcodecIndra
This is an old revision of this page, as it stood at 00:36, 1 Sep 2024, saved by IcodecIndra with the summary new article: compound, expansion welcome. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Oral semaglutide | |
|---|---|
| Active | Semaglutide |
| Enhancer | Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate |
| Bioavailability | ≈0.4–1% |
| Conditions | Fasting, ≤120 mL water, 30-minute wait |
| Compound infobox · conventions | |
Oral semaglutide is a tablet formulation of semaglutide co-formulated with the absorption enhancer sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, generally abbreviated SNAC. It was the first orally administered GLP-1 receptor agonist to be approved.[1]
Peptides are not orally bioavailable: gastric acid and proteases degrade them, and the intestinal epithelium excludes molecules of that size. SNAC addresses both by buffering the local gastric pH and transiently increasing local permeability, allowing absorption across the gastric mucosa itself rather than in the intestine.[2]
References
- ^ Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." Frontiers in Endocrinology 10:155 (2019). PMID 31031702.
- ^ Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." Science Translational Medicine 10(467):eaar7047 (2018). PMID 30429357.
Categories: